Semantic Scholar uses AI to extract papers important to this topic.
Background: The aim of this study was to prospectively analyse, for the first time worldwide by in vivo clinical confocal… Expand Depatuxizumab mafodotin (depatux-m, ABT-414) is a tumor-selective antibody drug conjugate (ADC) comprised of the anti-EGFR… Expand Background
We recently reported an acceptable safety and pharmacokinetic profile of depatuxizumab mafodotin (depatux-m), formerly… Expand Background
The purpose of this study was to determine the maximum tolerated dose (MTD), recommended phase II dose (RPTD), safety… Expand PurposePatients with recurrent glioblastoma (rGBM) have a poor prognosis. Epidermal growth factor receptor (EGFR) gene… Expand 2003Background: GBM is the most common malignant primary brain tumor in adults. Pts with rGBM have a poor prognosis. EGFR is… Expand Targeting tumor-overexpressed EGFR with an antibody–drug conjugate (ADC) is an attractive therapeutic strategy; however, normal… Expand 2542Background: Recurrent GBM (rGBM) has dismal prognosis. Almost 50% GBM tumors harbor amplified (amp) EGFR. ABT-414 is a tumor… Expand 2016 Background: GBM remains almost universally fatal and new therapies are needed. The epidermal growth factor receptor (EGFR… Expand 2021 Background: Patients (pts) with recurrent GBM have few treatment options and a very poor prognosis. GBM tumors often exhibit… Expand